Literature DB >> 21399662

Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity.

H Akita1, H Nagano, Y Takeda, H Eguchi, H Wada, S Kobayashi, S Marubashi, M Tanemura, H Takahashi, H Ohigashi, Y Tomita, O Ishikawa, M Mori, Y Doki.   

Abstract

The identification of molecular markers useful for predicting prognosis in pancreatic cancer patients is crucial for advances in disease management. The epithelial cell adhesion molecule (Ep-CAM) is known to express in most epithelial malignancies and was reported as a tumor marker or a candidate of molecular targeting therapy. However, the clinical significance of Ep-CAM expression in pancreatic cancer is not well-known. We determined the difference of malignant potential between parental and Ep-CAM-transfected pancreatic cancer cell lines by using proliferation, invasion and migration assay. Furthermore, we determined the relationship between tumoral Ep-CAM expression of resected specimens and clinical prognosis in 95 pancreatic cancer patients receiving radical surgery at two different cancer centers. One of the three Ep-CAM-transfected cell lines showed significantly low proliferation rate compared with the parental cell, while there was no difference in the other two cell lines. In invasion and migration assays, Ep-CAM-transfected cells showed significantly lower malignant potential than parental in all of the three cell lines. In 95 pancreatic cancer patients, 47 patients showed high-Ep-CAM expression, while 48 patients showed low, and there was no difference of clinicopathological features between Ep-CAM high and low-expression group. High-Ep-CAM expression group showed significantly good prognosis in overall survival (3-year survival; 56.2 versus 19.2%, P=0.0018) as well as in disease-free survival (3-year survival; 40.3 versus 14.4%, P=0.038) compared with low-expression group. In addition, the impact of Ep-CAM was observed strongly in LN-negative group when the influence of Ep-CAM was examined with dividing patients into LN-positive and negative group. In multivariate analysis, Ep-CAM expression was one of the independent prognostic factors as well as histology and lymph node metastasis. Ep-CAM expression was found to be related to the suppression of pancreatic cancer cell activity and the good prognosis in pancreatic cancer patients receiving the curative resection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21399662     DOI: 10.1038/onc.2011.59

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  EpCAM and its potential role in tumor-initiating cells.

Authors:  Sannia Imrich; Matthias Hachmeister; Olivier Gires
Journal:  Cell Adh Migr       Date:  2012 Jan-Feb       Impact factor: 3.405

2.  Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas.

Authors:  Kristi Ward; Clarissa Amaya; Kundan Verma; Dat Tran; Dolores Diaz; Alireza Torabi; Brad A Bryan
Journal:  Mol Clin Oncol       Date:  2014-09-25

3.  Epithelial cell adhesion molecule (EpCAM) regulates claudin dynamics and tight junctions.

Authors:  Chuan-Jin Wu; Poonam Mannan; Michael Lu; Mark C Udey
Journal:  J Biol Chem       Date:  2013-03-13       Impact factor: 5.157

4.  Histological and prognostic importance of CD44(+) /CD24(+) /EpCAM(+) expression in clinical pancreatic cancer.

Authors:  Yusuke Ohara; Tatsuya Oda; Masato Sugano; Shinji Hashimoto; Tsuyoshi Enomoto; Keiichi Yamada; Yoshimasa Akashi; Ryoichi Miyamoto; Akihiko Kobayashi; Kiyoshi Fukunaga; Yukio Morishita; Nobuhiro Ohkohchi
Journal:  Cancer Sci       Date:  2013-06-24       Impact factor: 6.716

5.  Overexpression of epithelial cell adhesion molecule protein is associated with favorable prognosis in an unselected cohort of ovarian cancer patients.

Authors:  Marco Johannes Battista; Cristina Cotarelo; Sina Jakobi; Joscha Steetskamp; Georgios Makris; Isabel Sicking; Veronika Weyer; Marcus Schmidt
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-13       Impact factor: 4.553

6.  Cytoplasmic EpCAM over-expression is associated with favorable clinical outcomes in pancreatic cancer patients with Hepatitis B virus negative infection.

Authors:  Yao Meng; Bao-Qing Xu; Zhi-Guang Fu; Bo Wu; Bo Xu; Zhi-Nan Chen; Ling Li
Journal:  Int J Clin Exp Med       Date:  2015-12-15

7.  High interstitial fluid pressure is associated with low tumour penetration of diagnostic monoclonal antibodies applied for molecular imaging purposes.

Authors:  Markus Heine; Barbara Freund; Peter Nielsen; Caroline Jung; Rudolph Reimer; Heinrich Hohenberg; Uwe Zangemeister-Wittke; Hans-Juergen Wester; Georg H Lüers; Udo Schumacher
Journal:  PLoS One       Date:  2012-05-08       Impact factor: 3.240

8.  An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer.

Authors:  Mei-Ying Liao; Jun-Kai Lai; Mark Yen-Ping Kuo; Ruei-Min Lu; Cheng-Wei Lin; Ping-Chang Cheng; Kang-Hao Liang; Han-Chung Wu
Journal:  Oncotarget       Date:  2015-09-22

9.  L1 and epithelial cell adhesion molecules associated with gastric cancer progression and prognosis in examination of specimens from 601 patients.

Authors:  Yuan-Yu Wang; Li Li; Zhong-Sheng Zhao; Yong-Xiang Wang; Zai-Yuan Ye; Hou-Quan Tao
Journal:  J Exp Clin Cancer Res       Date:  2013-09-16

10.  Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.

Authors:  Tatsuzo Mizukami; Hirofumi Kamachi; Tomoko Mitsuhashi; Yosuke Tsuruga; Yutaka Hatanaka; Toshiya Kamiyama; Yoshihiro Matsuno; Akinobu Taketomi
Journal:  BMC Cancer       Date:  2014-09-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.